Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Institutional National Research Service Award (T32)
Project #
2T32CA009172-17
Application #
3532669
Study Section
Cancer Institutional Fellowship Review Committee (CT)
Project Start
1978-07-01
Project End
1996-03-31
Budget Start
1991-05-01
Budget End
1992-03-31
Support Year
17
Fiscal Year
1991
Total Cost
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
149617367
City
Boston
State
MA
Country
United States
Zip Code
02215
Kapp, Friedrich G; Perlin, Julie R; Hagedorn, Elliott J et al. (2018) Protection from UV light is an evolutionarily conserved feature of the haematopoietic niche. Nature 558:445-448
Jenkins, Russell W; Aref, Amir R; Lizotte, Patrick H et al. (2018) Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discov 8:196-215
Lo, Justin H; Hao, Liangliang; Muzumdar, Mandar D et al. (2018) iRGD-guided Tumor-penetrating Nanocomplexes for Therapeutic siRNA Delivery to Pancreatic Cancer. Mol Cancer Ther 17:2377-2388
Gannon, Hugh S; Zou, Tao; Kiessling, Michael K et al. (2018) Identification of ADAR1 adenosine deaminase dependency in a subset of cancer cells. Nat Commun 9:5450
Boija, Ann; Klein, Isaac A; Sabari, Benjamin R et al. (2018) Transcription Factors Activate Genes through the Phase-Separation Capacity of Their Activation Domains. Cell 175:1842-1855.e16
Lampson, Benjamin L; Brown, Jennifer R (2018) Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia? Expert Rev Hematol 11:185-194
Aref, Amir R; Campisi, Marco; Ivanova, Elena et al. (2018) 3D microfluidic ex vivo culture of organotypic tumor spheroids to model immune checkpoint blockade. Lab Chip 18:3129-3143
Lampson, Benjamin L; Brown, Jennifer R (2017) PI3K?-selective and PI3K?/?-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma. Expert Opin Investig Drugs 26:1267-1279
Lampson, Benjamin L; Davids, Matthew S (2017) The Development and Current Use of BCL-2 Inhibitors for the Treatment of Chronic Lymphocytic Leukemia. Curr Hematol Malig Rep 12:11-19
Meehan, Terrence F; Conte, Nathalie; Goldstein, Theodore et al. (2017) PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models. Cancer Res 77:e62-e66

Showing the most recent 10 out of 241 publications